REVIEW

New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer
Sucharita J. Mistry and William K. Oh

CHEMICAL THERAPEUTICS

A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Hidetoshi Kuruma, Hiroaki Matsumoto, Masaki Shiota, Jennifer Bishop, Francois Lamoureux, Christian Thomas, David Briere, Gerrit Los, Martin Gleave, Andrea Fanjul, and Amina Zoubeidi

Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Warren Fiskus, Srdan Verstovsek, Taghi Manshouri, Jacqueline E. Smith, Karissa Peth, Sunil Abhyankar, Joseph McGuirk, and Kapil N. Bhalla

Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
Takashi Ninomiya, Nagio Takigawa, Eiki Ichihara, Nobuaki Ochi, Toshi Murakami, Yoshihiro Honda, Toshi Kubo, Daisuke Minami, Kenichiro Kudo, Mitsune Tanimoto, and Katsuyuki Kiura

Tandutinib Inhibits the Akt/mTOR Signaling Pathway to Inhibit Colon Cancer Growth
Sivapriya Ponnurangam, David Standing, Parthasarathy Rangarajan, and Dharmalingam Subramaniam

Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents
Heng Yang, Christie E. Pinello, Jian Luo, Dawei Li, Yunfei Wang, Lisa Y. Zhao, Stephan C. Jahn, Sanjay Adrian Saldanha, Jamie Planck, Kyla R. Geary, Haiching Ma, Brian K. Law, William R. Roush, and Daiqing Liao

SMALL MOLECULE THERAPEUTICS

Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Nicholas G. Nickols, Jerzy O. Szablowski, Amanda E. Hargrove, Benjamin C. Li, Jevgenij A. Raskatov, and Peter B. Dervan

Spongian Diterpenoids Inhibit Androgen Receptor Activity
Yu Chi Yang, Labros G. Meimitis, Amy H. Tien, Nasrin R. Mawji, Gavin Carr, Jun Wang, Raymond J. Andersen, and Marianne D. Sadar

Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells

Regression of Lung Cancer by Hypoxia-Sensitizing Ruthenium Poly(pyridyl) Complexes
Abhishek Yadav, Thamara Janaratne, Arthi Krishnan, Sharad S. Singhal, Sushma Yadav, Adam S. Dayoub, Doyle L. Hawkins, Sanjay Awasthi, and Frederick M. MacDonnell

Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy

A Novel Sulindac Derivative Inhibits Lung Adenocarcinoma Cell Growth through Suppression of Akt/mTOR Signaling and Induction of Autophagy
Evrim Gurpinar, William E. Grizzle, John J. Shacka, Burton J. Mader, Nan Li, Nicholas A. Piazza, Suzanne Russo, Adam B. Keeton, and Gary A. Piazza
**LARGE MOLECULE THERAPEUTICS**

685 | A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth
Emily Fontenot, Emma Rossi, Russell Mumper, Stephanie Snyder, Sharareh Siamakpour-Reihani, Ping Ma, Eleanor Hilliard, Bradley Bone, David Ketelsen, Charlene Santos, Cam Patterson, and Nancy Klauber-DeMore

759 | Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma
Zebin Wang, Yu Zheng, Hyun Jung Park, Jing Li, Janai R. Carr, Yi-ju Chen, Megan M. Kiefer, Dragana Kopanja, Srilata Bagchi, Angela L. Tyner, and Pradip Raychaudhuri

**CANCER THERAPEUTICS INSIGHTS**

696 | ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non–Small Cell Lung Cancer Expressing EML4-ALK
Yunguang Sun, Kamila A. Nowak, Nicholas G. Zaorsky, Chia-Lin Winchester, Kunal Dalal, Nicholas J. Giacalone, Ningbo Liu, Maria Werner-Wasik, Mariusz A. Wasik, Adam P. Dicker, and Bo Lu

777 | Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells
Xingnan Zheng, Kan He, Lin Zhang, and Jian Yu

787 | Impact of Tumor Vascularity on Responsiveness to Antiangiogenesis in a Prostate Cancer Stem Cell-Derived Tumor Model
Kexiong Zhang and David J. Waxman

809 | A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter
Daniel Hochhauser, Rob Glynn-Jones, Vanessa Potter, Cristina Grávalos, Thomas J. Doyle, Kumudu Pathiraja, Qing Zhang, Ling Zhang, and Edward A. Sausville

**TOOLS & TECHNOLOGIES**

777 | Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death
Grazia Ambrosini, Elgilda Musi, Alan L. Ho, Elisa de Stanchina, and Gary K. Schwartz

799 | Targeting CXCIR2 Enhances Chemotherapeutic Response, Inhibits Mammary Tumor Growth, Angiogenesis, and Lung Metastasis
Bhawna Sharma, Dhananjay M. Nawandar, Kalyan C. Nannuru, Michelle L. Varney, and Rakesh K. Singh

819 | [18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941
Christopher Cawthorne, Natalie Burrows, Roben G. Gieling, Christopher J. Morrow, Duncan Forster, Jamil Gregory, Marc Radigois, Alison Smigova, Muhammad Babur, Kathryn Simpson, Cassandra Hodkinson, Gavin Brown, Adam McMahon, Caroline Dive, Duncan Hiscock, Ian Wilson, and Kaye J. Williams

American Association for Cancer Research
ABOUT THE COVER

Mitochondria is the powerhouse of cells (structure, green), supplying the majority of ATP that is essential for cell survival. However, cancer cells present a distinct glycolytic metabolism profile (Warburg effect), which is linked to the malignant transformation process. The emerging anti-VEGF therapy fights cancers by starving the energy supplement, but it was found to enhance the Warburg effect and induce even more aggressive phenotypes. Cancer cells with acquired resistance to anti-VEGF therapy display impaired mitochondria structure and hyperactive glycolytic metabolism, which render them vulnerable to glycolysis blockade therapy. For details, see article by Xu and colleagues on page 717.